Vivani Medical Q2 net loss narrows as expenses fall

Vivani Medical

13/08/2026 22:28

Overview
US biopharmaceutical developer's Q2 net loss narrowed compared to prior yr
Vivani entered non-exclusive agreement with Novo Nordisk to evaluate NPM-139 implant

Outlook
Vivani anticipates completion of Cortigent-ClearOne merger in Q3 2026

Result Drivers
LOWER EXPENSES - Decreases in R&D and general and administrative expenses contributed to narrower net loss

Company press release: ID:nGNX8HXcz6

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.07
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vivani Medical Inc is $4.00, about 192% above its August 12 closing price of $1.37

Reuters Recommended Reads
Aug 13 - Novo CEO says obesity market won't be winner-take-all battle with Lilly
Aug 13 - Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Aug 13 - Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)